Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2023

Revenue Recognition

Schedule of disaggregation of revenue

	Three Months Ended March 31,
	2023		2022
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	2,750	$	—
Total collaborative revenue	$	2,750	$	—
Commercial supply revenue
CSL Vifor* (KORSUVA injection)	$	3,191	$	4,790
Total commercial supply revenue	$	3,191	$	4,790
Royalty revenue
CSL Vifor (Kapruvia ex U.S.)	$	125	$	—
Total royalty revenue	$	125	$	—
Clinical compound revenue
Maruishi	$	99	$	—
Total clinical compound revenue	$	99	$	—

_____________________________

* Includes amounts earned from Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.